Skip to main content

Akari Therapeutics, PLC (AKTX)

NASDAQ: AKTX · IEX Real-Time Price · USD
1.70 0.00 (0.00%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap80.92M
Revenue (ttm)n/a
Net Income (ttm)-15.56M
Shares Out3.85B
EPS (ttm)-0.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume133,055
Open1.70
Previous Close1.70
Day's Range1.67 - 1.75
52-Week Range1.42 - 4.21
Beta1.23
AnalystsStrong Buy
Price Target5.00 (+194.1%)
Est. Earnings Daten/a

About AKTX

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pem...

IndustryPharmaceuticals
CEODavid Solomon
Employees9
Stock ExchangeNASDAQ
Ticker SymbolAKTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for AKTX stock is "Strong Buy" and the 12-month stock price forecast is 5.00.

Price Target
$5.00
(194.12% upside)
Analyst Consensus: Strong Buy

News

Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress

NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...

3 days ago - GlobeNewsWire

Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 Inter...

NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...

2 weeks ago - GlobeNewsWire

Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference

NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...

2 weeks ago - GlobeNewsWire

Akari Therapeutics Announces Private Placement

NEW YORK and LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan a...

2 months ago - GlobeNewsWire

Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress

NEW YORK and LONDON, June 29, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

2 months ago - GlobeNewsWire

Akari Therapeutics' Nomacopan Secures Expediated Review Tag For Blistering Skin Disorder

The FDA has granted Fast Track designation to Akari Therapeutics Plc's (NASDAQ: AKTX) nomacopan to treat patients with moderate and severe Bullous Pemphigoid (BP). Nomacopan has also been granted orphan...

4 months ago - Benzinga

Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at...

NEW YORK and LONDON, April 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory...

5 months ago - GlobeNewsWire

Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress

NEW YORK and LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...

5 months ago - GlobeNewsWire

Akari Therapeutics' To Go With Pivotal Bullous Pemphigoid Study With Nomacopan

The FDA has opened the investigational new drug application for Phase 3 trial for Akari Therapeutics Plc's (NASDAQ: AKTX) lead drug candidate, nomacopan, for the treatment of moderate and severe Bullous...

5 months ago - Benzinga

Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)

FDA investigational new drug application (IND) now open

5 months ago - GlobeNewsWire

Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of...

Study of porcine model of blast injury and haemorrhagic shock underway with USAISR as part of the development of a clinical path for the use of nomacopan to treat trauma Study of porcine model of blast ...

6 months ago - GlobeNewsWire

Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies

Akari Therapeutics Plc (NASDAQ: AKTX) announces new data from PASylated nomacopan published in the journal CELLS. In a non-infectious allergic uveitis animal model, PAS-nomacopan reduced VEGF by more th...

7 months ago - Benzinga

Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat R...

NEW YORK and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

7 months ago - GlobeNewsWire

Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease

NEW YORK and LONDON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

7 months ago - GlobeNewsWire

Akari Therapeutics to Participate in Two January Virtual Investor Conferences

NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

8 months ago - GlobeNewsWire

Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress

NEW YORK and LONDON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

9 months ago - GlobeNewsWire

Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and ...

NEW YORK and LONDON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

9 months ago - GlobeNewsWire

Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Trea...

NEW YORK and LONDON, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory ...

9 months ago - GlobeNewsWire

Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Vene...

NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory ...

10 months ago - GlobeNewsWire

Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia

NEW YORK and LONDON, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory ...

11 months ago - GlobeNewsWire

Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishi...

NEW YORK and LONDON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory ...

11 months ago - GlobeNewsWire

Akari Therapeutics to Present Its Phase III Plans at the International Pemphigus & Pemphigoid Foundation (IPPF) Patie...

NEW YORK and LONDON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...

11 months ago - GlobeNewsWire

Akari Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Recent Clinical Progress

NEW YORK and LONDON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...

1 year ago - GlobeNewsWire

Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of C...

NEW YORK and LONDON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a Phase III biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and ...

1 year ago - GlobeNewsWire

Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Trea...

NEW YORK and LONDON, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammator...

1 year ago - GlobeNewsWire